Transdermal drug delivery co kickstarts $5.7m series A:
This article was originally published in Clinica
Executive Summary
Ruggell, Liechtenstein-based drug delivery company Pantec Biosolutions is initiating a SwFr6.3m ($5.67m) series A financing, which will be led by Austrian VC Gamma Capital Partners. Pantec intends to use the funds to advance the development of its laser microporation device LEDDT (laser easy drug delivery technology). The system is designed to deliver transdermally large molecular weight compounds, such as hormones used for in vitro fertilisation (IVF) therapy. Current IVF regimes consist of daily injections of hormones over a period of several weekends.